Stay updated with breaking news from Hepatotoxins. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Packing can be stressful, especially when heading out for the holidays.Here to take one thing off your mind, Minute Clinic Family Nurse Practitioner, Amy Luebeh
People usually reach for the vitamin C or the hot tea when they have a cold, but which actually work?ALSO READ:How effective are self exams for breast cancer?D
Heart disease is the number one killer in the U.S. Now doctors are warning that the medications that could help prevent heart disease may be blocked by your ins
Granules India rose 1.57% to Rs 326.90 after the company said that US drug regulator has approved its Abbreviated New Drug Application (ANDA) for Acetaminophen, Aspirin and Caffeine Tablets USP, 250 mg/250 mg/65 mg (OTC).The product is bioequivalent to the reference listed drug product (RLD), Excedrin migraine tablets, 250 mg/250 mg/65 mg, of GlaxoSmithKline Consumer Healthcare. The drug is indicated for treating migraine. The product will be manufactured at the company's Hyderabad facility and is expected to be launched shortly. Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals, Inc., commenting on the approval, said: "We are pleased to announce approval of acetaminophen, aspirin and caffeine tablets, emphasizing our focus on building sustainable OTC product portfolio in the US market. We received approval for this triple combination product within 14 months from filing. With this, we have received three ANDA approvals over the past month."